Author: Matthew Nelson|| Date Published: January 28, 2021
Eli Lilly and Co. (NYSE: LLY) has secured a $625 million contract modification to supply 500,000 more doses of the company’s COVID-19 monoclonal antibody drug to the U.S. Army.
Army Contracting Command obligated the full amount of the modification using fiscal 2021 Coronavirus Aid, Relief and Economic Security Act funds, the Department of Defense said Wednesday.
In November, the Food and Drug Administration granted emergency use authorization for Lilly’s LY-CoV555 antibody drug as a treatment for patients 12 years and older who have mild to moderate COVID-19 and at risk of developing severe coronavirus infection.
Bamlanivimab is intended to be administered via intravenous infusion, the company noted.
CACI International has secured a potential five-year, $416 million SeaPort-Next Generation task order to sustain and modernize information technology systems…
Cherry Bekaert has acquired accounting and advisory firm Tarsus to expand outsourced accounting, real-time financial reporting and strategic chief financial…
General Dynamics Information Technology has received a U.S. Navy contract worth $988 million to modernize and integrate command, control, communications,…
Dave Wajsgras, an eight-time Wash100 Award winner, has been named chairman and CEO of Everfox. The cybersecurity company said Monday that Wajsgras will…
The Transportation Security Administration has announced a contract opportunity with an estimated value exceeding $100 million for enterprise-wide IT support…
